Balyasny Asset Management
NKTR icon

Balyasny Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Balyasny Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,667
Closed -$10.8M – 1630
2018
Q3 		$10.8M Buy
+12,667
New +$10.8M 0.05% 465
2018
Q2 		– Sell
-2,620
Closed -$4.18M – 2031
2018
Q1 		$4.18M Buy
+2,620
New +$3.38M 0.02% 764

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Balyasny Asset Management's NKTR Position: Q1 2026 in Review

Balyasny Asset Management reduced its Nektar Therapeutics (NKTR) stake by 87% in Q1 2026, selling an estimated $14M and leaving 35,851 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Balyasny Asset Management first reported a position in NKTR in Q2 2015 and has held it in 26 quarters since. The position peaked at $19M in Q3 2017. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Balyasny Asset Management held 35,851 shares of Nektar Therapeutics worth $2.58M as of Q1 2026.
  • Balyasny Asset Management sold 246,170 Nektar Therapeutics shares in Q1 2026, an estimated $14M.
  • Nektar Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1673 holding.
  • Balyasny Asset Management first reported a position in Nektar Therapeutics in Q2 2015 and has held it in 26 quarters since.
  • Balyasny Asset Management's Nektar Therapeutics position peaked at $19M in Q3 2017.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.